New News information at Pharmaceutical Technology New and updated information from News listed on www.pharmaceutical-technology.com http://www.pharmaceutical-technology.com/ en-us http://www.pharmaceutical-technology.com/ New News information at Pharmaceutical Technology http://www.pharmaceutical-technology.com/content/images/logo_big.gif Eisai seeks marketing authorisation for lenvatinib from EMA http://www.pharmaceutical-technology.com/news/newseisai-seeks-marketing-authorisation-for-lenvatinib-from-ema-5884508 http://www.pharmaceutical-technology.com/news/newseisai-seeks-marketing-authorisation-for-lenvatinib-from-ema-5884508 Eisai has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for first-line use of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC). Thu, 27 Jul 2017 23:00:00 GMT Deals this week: Fidson Healthcare, Sarepta Therapeutics, North China Pharmaceutical http://www.pharmaceutical-technology.com/news/newsdeals-this-week-fidson-healthcare-sarepta-therapeutics-north-china-pharmaceutical-5883403 http://www.pharmaceutical-technology.com/news/newsdeals-this-week-fidson-healthcare-sarepta-therapeutics-north-china-pharmaceutical-5883403 Nigerian pharmaceutical company Fidson Healthcare plans to raise NGN6bn ($18.65m) through a rights offering of shares. Thu, 27 Jul 2017 23:00:00 GMT AstraZeneca’s faslodex receives EU approval for advanced breast cancer treatment http://www.pharmaceutical-technology.com/news/newsastrazenecas-faslodex-receives-eu-approval-for-advanced-breast-cancer-treatment-5883683 http://www.pharmaceutical-technology.com/news/newsastrazenecas-faslodex-receives-eu-approval-for-advanced-breast-cancer-treatment-5883683 The European Commission (EC) has approved AstraZeneca’s faslodex (fulvestrant) for the treatment of oestrogen-receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. Thu, 27 Jul 2017 23:00:00 GMT ViiV reaches another milestone http://www.pharmaceutical-technology.com/news/newsviiv-reaches-another-milestone-5884701 http://www.pharmaceutical-technology.com/news/newsviiv-reaches-another-milestone-5884701 On July 24, 2017, ViiV Healthcare announced positive results from 96-week data obtained from a Phase IIb, open-label study (LATTE-2) investigating the safety and efficacy of a two-drug, long-acting injectable anti-HIV formulation composed of ViiV’s c… Thu, 27 Jul 2017 15:24:00 GMT ViiV reaches another milestone in the development of a long-acting HIV regimen http://www.pharmaceutical-technology.com/news/newsviiv-reaches-another-milestone-in-the-development-of-a-long-acting-hiv-regimen-5884700 http://www.pharmaceutical-technology.com/news/newsviiv-reaches-another-milestone-in-the-development-of-a-long-acting-hiv-regimen-5884700 On July 24, 2017, ViiV Healthcare announced positive results from 96-week data obtained from a Phase IIb, open-label study (LATTE-2) investigating the safety and efficacy of a two-drug, long-acting injectable anti-HIV formulation composed of ViiV’s c… Thu, 27 Jul 2017 15:21:00 GMT FDA grants fast-track status for Ablynx’s caplacizumab to treat aTTP http://www.pharmaceutical-technology.com/news/newsfda-grants-fast-track-designation-for-ablynxs-caplacizumab-to-treat-attp-5883181 http://www.pharmaceutical-technology.com/news/newsfda-grants-fast-track-designation-for-ablynxs-caplacizumab-to-treat-attp-5883181 Belgian biopharmaceutical company Ablynx has received fast-track designation from the US Food and Drug Administration (FDA) for its caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (aTTP). Wed, 26 Jul 2017 23:00:00 GMT Sandoz to improve treatment access to children with cancer in four developing nations http://www.pharmaceutical-technology.com/news/newssandoz-to-improve-treatment-access-to-children-with-cancer-in-four-developing-nations-5883115 http://www.pharmaceutical-technology.com/news/newssandoz-to-improve-treatment-access-to-children-with-cancer-in-four-developing-nations-5883115 Novartis Group division Sandoz has expanded its partnership with UK-based charity World Child Cancer to improve access to treatment, as well as optimise survival outcomes for children suffering from cancer in four developing nations. Wed, 26 Jul 2017 23:00:00 GMT New study discovers faulty genes underlying brain tumours http://www.pharmaceutical-technology.com/news/newsnew-study-discovers-faulty-genes-underlying-brain-tumours-5882983 http://www.pharmaceutical-technology.com/news/newsnew-study-discovers-faulty-genes-underlying-brain-tumours-5882983 A new in-depth study funded by Cancer Research UK has shown that medulloblastoma brain tumours have faulty genes underlying the disease. Wed, 26 Jul 2017 23:00:00 GMT Antabio to develop treatment for Pseudomonas infections in cystic fibrosis patients http://www.pharmaceutical-technology.com/news/newsantabio-to-develop-pseudomonas-infections-treatment-in-cystic-fibrosis-5882155 http://www.pharmaceutical-technology.com/news/newsantabio-to-develop-pseudomonas-infections-treatment-in-cystic-fibrosis-5882155 French biopharmaceutical company Antabio has secured a non-dilutive funding to accelerate the development of a new small molecule drug to treat chronic Pseudomonas infections in cystic fibrosis patients. Tue, 25 Jul 2017 23:00:00 GMT GSK files supplementary NDA for asthma treatment arnuity ellipta http://www.pharmaceutical-technology.com/news/newsgsk-files-supplementary-nda-for-asthma-treatment-arnuity-ellipta-5881393 http://www.pharmaceutical-technology.com/news/newsgsk-files-supplementary-nda-for-asthma-treatment-arnuity-ellipta-5881393 GSK has submitted a supplementary new drug application (sNDA) to the US Food and Drug Administration (FDA) for the use of arnuity ellipta (fluticasone furoate) as a maintenance treatment of children with asthma. Tue, 25 Jul 2017 23:00:00 GMT STA Pharmaceutical signs deal with Tesaro for zejula http://www.pharmaceutical-technology.com/news/newssta-pharmaceutical-signs-deal-with-tesaro-for-zejula-5881345 http://www.pharmaceutical-technology.com/news/newssta-pharmaceutical-signs-deal-with-tesaro-for-zejula-5881345 STA Pharmaceutical, a subsidiary of China-based company WuXi AppTec with facilities in China and the US, has signed a new supply agreement with oncology-focused biopharmaceutical company Tesaro for certain starting and intermediate materials for zeju… Tue, 25 Jul 2017 23:00:00 GMT Janssen receives EMA committee recommendation to market Symtuza for HIV http://www.pharmaceutical-technology.com/news/newsjanssen-gets-ema-committee-recommendation-to-market-symtuza-for-hiv-5881107 http://www.pharmaceutical-technology.com/news/newsjanssen-gets-ema-committee-recommendation-to-market-symtuza-for-hiv-5881107 Janssen-Cilag International (Janssen) has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Symtuza for the treatment of HIV. Mon, 24 Jul 2017 23:00:00 GMT Mitsubishi Tanabe Pharma to buy NeuroDerm for $1.1bn http://www.pharmaceutical-technology.com/news/newsmitsubishi-tanabe-pharma-to-buy-neuroderm-for-11bn-5880613 http://www.pharmaceutical-technology.com/news/newsmitsubishi-tanabe-pharma-to-buy-neuroderm-for-11bn-5880613 Japan’s Mitsubishi Tanabe Pharma (MTPC) has entered a new definitive agreement to acquire all of the outstanding shares of Israel-based pharmaceutical company NeuroDerm for $1.1bn in cash. Mon, 24 Jul 2017 23:00:00 GMT Lilly and Nektar partner to develop new immunological therapy NKTR-358 http://www.pharmaceutical-technology.com/news/newseli-lilly-and-nektar-partner-to-develop-new-immunological-therapy-nktr-358-5880521 http://www.pharmaceutical-technology.com/news/newseli-lilly-and-nektar-partner-to-develop-new-immunological-therapy-nktr-358-5880521 Eli Lilly and Company has entered a strategic collaboration to co-develop Nektar Therapeutics’ new immunological therapy NKTR-358. Mon, 24 Jul 2017 23:00:00 GMT EMA’s CHMP recommends Merck and Pfizer's cancer drug avelumab for approval http://www.pharmaceutical-technology.com/news/newsemas-chmp-recommends-merck-and-pfizers-cancer-drug-avelumab-for-approval-5879925 http://www.pharmaceutical-technology.com/news/newsemas-chmp-recommends-merck-and-pfizers-cancer-drug-avelumab-for-approval-5879925 The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Merck and Pfizer's avelumab (BAVENCIO) as a monotherapy to treat adult patients with metastatic Mer… Sun, 23 Jul 2017 23:00:00 GMT Recipharm and LIDDS set up prostate cancer drug development facility in Sweden http://www.pharmaceutical-technology.com/news/newsrecipharm-and-lidds-sets-up-prostate-cancer-drug-development-facility-in-sweden-5878160 http://www.pharmaceutical-technology.com/news/newsrecipharm-and-lidds-sets-up-prostate-cancer-drug-development-facility-in-sweden-5878160 Recipharm, a Swedish contract development and manufacturing organisation (CDMO), and LIDDS have jointly established an industrial manufacturing line to develop new prostate cancer drug, Liproca Depot. Sun, 23 Jul 2017 23:00:00 GMT NICE approves new tolerable drug carflizomib for multiple myeloma patients on NHS http://www.pharmaceutical-technology.com/news/newsnice-approves-new-tolerable-drug-carflizomib-for-multiple-myeloma-patients-on-nhs-5877024 http://www.pharmaceutical-technology.com/news/newsnice-approves-new-tolerable-drug-carflizomib-for-multiple-myeloma-patients-on-nhs-5877024 UK’s National Institute for Health and Care Excellence (NICE) has approved Amgen’s new anti-cancer treatment carflizomib for multiple myeloma patients on the National Health Service (NHS). Sun, 23 Jul 2017 23:00:00 GMT Deals this week: Hugel, Guangdong Zhongsheng Pharmaceutical, Valeant Pharmaceuticals International http://www.pharmaceutical-technology.com/news/newsdeals-this-week-hugel-guangdong-zhongsheng-pharmaceutical-valeant-pharmaceuticals-international-5876058 http://www.pharmaceutical-technology.com/news/newsdeals-this-week-hugel-guangdong-zhongsheng-pharmaceutical-valeant-pharmaceuticals-international-5876058 South Korean pharmaceutical company Hugel has announced the private placement of 985,217 common stock shares priced at KRW360,001.9 ($316.2) a share to raise KRW354.68bn ($311.52m) in gross proceeds. Thu, 20 Jul 2017 23:00:00 GMT M&As this week: Northeast Pharmaceutical Group, Principia SGR, Commelina http://www.pharmaceutical-technology.com/news/newsmas-this-week-northeast-pharmaceutical-group-principia-sgr-commelina-limited-5876066 http://www.pharmaceutical-technology.com/news/newsmas-this-week-northeast-pharmaceutical-group-principia-sgr-commelina-limited-5876066 Chinese pharmaceutical company Northeast Pharmaceutical Group plans to acquire 60% stake in a medicine company based in Dandong, China, through its subsidiary for CNY3.9m ($0.57m). Thu, 20 Jul 2017 23:00:00 GMT NICE recommends Teva’s Cinqaero to treat severe eosinophilic asthma http://www.pharmaceutical-technology.com/news/newsnice-recommends-tevas-cinqaero-to-treat-severe-eosinophilic-asthma-5877549 http://www.pharmaceutical-technology.com/news/newsnice-recommends-tevas-cinqaero-to-treat-severe-eosinophilic-asthma-5877549 The UK National Institute for Health and Care Excellence (NICE) has recommended Teva Pharmaceutical Industries’ Cinqaero (reslizumab) for the treatment of patients with severe eosinophilic asthma. Thu, 20 Jul 2017 23:00:00 GMT